Google
TBPH — THERAVANCE BIOPHARMA INC (Healthcare >> Biotechnology)
TBPH FAQ
What is TBPH's P/E ratio?
THERAVANCE BIOPHARMA INC (TBPH) currently trades at a P/E ratio of 7.16.
What is TBPH's ROE?
THERAVANCE BIOPHARMA INC reports a Return on Equity (ROE) of 39.42%.
What is TBPH's dividend yield?
THERAVANCE BIOPHARMA INC offers a dividend yield of 0.00%.
What is TBPH's Deepscope Quality Score?
Deepscope rates TBPH's overall financial quality at 77 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TBPH?
Deepscope's AI Timing Score for TBPH is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TBPH belong to?
THERAVANCE BIOPHARMA INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 16.29
Price
-0.08
(-0.49%)
Day Change
|
|
|---|
TBPH, the overall quality is good ( Quality = 77) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
Acceleration of ROE growth rate is below our criteria.
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
60% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
118
|
| Magic Formula Rank by ROE |
118
|
| Magic Formula Rank by ROIC |
108
|
| Price | 16.29 |
| PBV / Sector |
2.94 / 4.63
|
| Earning Per Share | 2.18 |
| PE / Sector |
7.16 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
-0.06 / 0.53
|
| Average 1M Daily Value |
6.14 M
|
| Average 1W Daily Value |
6.89 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
47% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:44 |
| Symbol | TBPH |
| Name | THERAVANCE BIOPHARMA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 51.55 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 855.78 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 808 6000
Website: https://www.theravance.com
Employees: 90
Sector: Healthcare >> Biotechnology
Description: Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
